Identification of a Novel Eight-lncRNA Prognostic Signature for HBV-HCC and Analysis of Their Functions Based on Coexpression and ceRNA Networks
Table 2
Univariate and multivariate analyses of the lncRNA signature and survival.
Features
TCGA ()
Univariate cox
Multivariate cox
HR (95% CI)
value
HR (95% CI)
value
Age (, years)
1.039 (1.008-1.070)
1.26-02
1.004 (0.976-1.034)
7.66-01
Gender (male/female)
58/37
1.296 (0.661-2.544)
4.49-01
—
—
Neoplasm histologic grade (G1/G2/G3)
12/47/36
1.071 (0.646-1.775)
7.91-01
—
—
Pathologic M (M0/M1/-)
60/2/33
1.088 (0.919-10.28)
6.33-01
—
—
Pathologic N (N0/N1/-)
59/2/34
1.178 (0.849-16.23)
1.47-01
—
—
Pathologic T (T1/T2/T3/T4/-)
38/33/21/2/1
1.131 (0.752-1.700)
5.55-01
—
—
Pathologic stage (stage I/II/III/IV)
36/30/22/2
1.037 (0.697-1.543)
8.57-01
—
—
Vascular invasion (yes/no/-)
38/47/10
2.421 (1.232-4.756)
8.12-03
2.113 (1.013-4.408)
4.63-02
Tumor recurrence (yes/no)
38/57
2.321 (1.217-4.429)
8.56-03
1.664 (1.213-3.405)
4.16-02
Risk score status (high/low)
48/47
4.666 (2.204-9.880)
1.38-05
3.198 (1.424-7.184)
4.88-03
Death (dead/alive)
38/57
—
—
—
—
Overall survival time (, months)
—
—
—
—
SD: standard deviation; TCGA: The Cancer Genome Atlas; HR: hazard ratio; CI: confidence interval. Bold indicates the results with statistical significance ().
